IPP Bureau
Pharmaceutical sector set for 8-10% revenue growth this fiscal: CRISIL
By IPP Bureau - September 20, 2024
Stable profits, low leverage to keep credit profiles comfortable
AstraZeneca Pharma India to launch Palivizumab (Synagis) in October 2024
By IPP Bureau - September 20, 2024
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by RSV in children at high risk for RSV disease
Suven Pharmaceuticals names Vivek Sharma as Executive Chairman
By IPP Bureau - September 20, 2024
Based out of Boston, Vivek will build on the foundation created by Vaidheesh, and will help build a stronger customer connect and further drive global expansion of the platform
Wockhardt's Zaynich cures complex case of meningitis caused by pan-drug resistant super-bug under compassionate use
By IPP Bureau - September 20, 2024
A multi-disciplinary team of senior physicians opted to use Zidebactam/Cefepime under compassionate use
Briefs: Fermenta Biotech and Family Care Hospitals
By IPP Bureau - September 20, 2024
Fermenta Biotech’s API manufacturing facility receives EU GMP compliance certificate
Abbott India inks non-exclusive patent license agreement with Takeda for Vonoprazan
By IPP Bureau - September 20, 2024
This license will enable Abbott to enhance access to this novel therapy to more patients across India
MGC inks agreement to revolutionize allergy care
By IPP Bureau - September 20, 2024
Dr. Girish Budhrani recognised with ACOIN Gujarat Chapter Oration
By IPP Bureau - September 20, 2024
ACOIN has recognized Dr. Budhrani's exceptional work in promoting community and clinical ophthalmology
Briefs: Dr. Reddy's Laboratories and Torrent Pharmaceuticals
By IPP Bureau - September 20, 2024
USFDA concludes inspection of Dr. Reddy's Laboratories R&D centre in Bachupally with zero observation
Merck receives positive EU CHMP opinions for pembrolizumab regimens for gynecologic cancers
By IPP Bureau - September 20, 2024
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma
Shilpa Biologicals appoints Dr. Sridevi Khambhampaty as CEO
By IPP Bureau - September 20, 2024
She brings an overall Techno Commercial experience of 22+ Years in various Organizations
Aurobindo Pharma to acquire balance 49% stake in GLS Pharma
By IPP Bureau - September 19, 2024
Lupin receives USFDA approval for Bumetanide Injection
By IPP Bureau - September 19, 2024
Bumetanide Injection USP (RLD Bumex) had estimated annual sales of USD 20 million in the U.S.
Roche receives USFDA approval for Ocrevus Zunovo for treatment of progressive multiple sclerosis
By IPP Bureau - September 19, 2024
This approval is backed by a decade of proven safety and efficacy data of Ocrevus® IV, with over 350,000 people treated globally
Fasenra approved in the US for eosinophilic granulomatosis with polyangiitis
By IPP Bureau - September 19, 2024
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
